REGN Stock Price Today (September 2026) — Regeneron Pharmaceuticals, Inc. Analysis & Key Metrics 2026-09-03
Regeneron Pharmaceuticals, Inc. (REGN) is trading at $843.47, down 1.00% today (as of September 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $833.54 (-1.2% upside).
- Volatility remains elevated (25.33% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (16.70% YoY) alongside significant competitive pressures.
REGN Stock Analysis: Key Metrics & Valuation (September 2026)
Concise, actionable data for investors
Regeneron Pharmaceuticals, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $74.02B
P/E Ratio
Forward P/E: 13.18
Revenue Growth
Year over Year
Analyst Target
+-1.2% upside potential
Key Investor Questions About REGN
What investors need to know before buying
Based on current market data, REGN presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 66.43)
- Fundamentals say: Caution warranted (high leverage concerns)
REGN's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for REGN investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $2.71B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, REGN stock traded between $541.00 and $847.00—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 25.33% annualized volatility and β=0.65, the stock exhibits low sensitivity to market moves—making REGN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
Veeva Systems (NYSE: VEEV) announced that Regeneron and Biogen have adopted its AI powered Vault CRM suite globally. The company also introduced Veeva Falcon Safety, a new agentic safety operations product for biopharma clients. Both moves expand Veeva Systems' AI focused offering across commercial and safety workflows in life sciences. These updates highlight how AI heavy software is becoming core infrastructure for healthcare and biopharma workflows. This connects directly to a wider set...
Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?
Regeneron Pharmaceuticals has outpaced the healthcare sector, and analysts remain moderately optimistic about the stock’s outlook.
Regeneron Pharmaceuticals (REGN) As Pasatru Approval Tests An Undervalued View
Regeneron Pharmaceuticals (REGN) is back in focus after the FDA approved Pasatru garetosmab grts for adults with fibrodysplasia ossificans progressiva, following positive Phase 3 OPTIMA trial data on heterotopic ossification lesion reduction. Regeneron Pharmaceuticals shares trade at US$794.19 after a recent pullback, with the 7 day share price return down 4.78% and the 90 day share price return up 32.22%. The 1 year total shareholder return of 37.47% points to momentum that has built over a...
Regeneron Pharmaceuticals (REGN) Wins FDA Approval For Pasatru In Adult FOP
Regeneron Pharmaceuticals (NasdaqGS: REGN) received FDA approval for Pasatru TM (garetosmab grts) to treat adults with fibrodysplasia ossificans progressiva. The approval is based on a positive Phase 3 trial in this rare and severely debilitating condition. Pasatru adds a new rare disease therapy to Regeneron's portfolio and introduces a fresh product-based revenue stream. This kind of targeted drug development in rare diseases is part of a wider shift toward more data driven healthcare,...
SNY Stock Trading Above 50- & 200-Day SMAs: Buy, Hold or Sell?
Sanofi's stock trades above key moving averages as Dupixent and new drugs drive growth, while pipeline setbacks and vaccine weakness weigh.
Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?
The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progressiva. FOP is an ultra-rare genetic disorder in which bone forms inside muscles, tendons, and ligaments, progressively restricting movement. In a 56-week Phase 3 trial involving 63 adults, the approved 3-milligram-per-kilogram dose reduced the number of […]
Amgen, AstraZeneca Score With Tezspire; Can They Take On Dupixent?
Amgen and AstraZeneca's drug, Tezspire, scored Thursday in an esophageal disease that affects an estimated 470,000 patients in the U.S.
Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials
Sound Shore Management, an investment management firm, has released its investor letter for the second quarter of 2026. The letter can be downloaded here. The Sound Shore Fund’s Investor Class (SSHFX) and Institutional Class (SSHVX) rose 10.48% and 10.58% in the second quarter of 2026, trailing the Russell 1000 Value Index’s 13.87% and the S&P 500’s […]
Veeva Systems Q2 Earnings Call Highlights
Veeva Systems (NYSE:VEEV) reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded the company’s guidance. Management highlighted record CRM performance, broad commercial-cloud moment
Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?
Regeneron Pharmaceuticals has comfortably outperformed the S&P 500 over the past year, and Wall Street remains reasonably bullish on the company’s long-term growth prospects.
Explore More Analysis for REGN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) is currently trading at $843.47. The RSI (14-day) is at 66.4, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $833.54 implies 1.2% downside from current levels. Volatility is moderate at 25.3% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Regeneron Pharmaceuticals, Inc. (REGN): The trailing P/E ratio is 20.87, which is in line with broader market averages. The forward P/E is 13.18, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.33, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 2.67. Price-to-Sales is 5.49. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 27 analysts covering REGN, the consensus price target is $833.54. This represents a 1.2% downside from the current price of $843.47. The range spans from a low target of $641.00 to a high target of $1030.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Regeneron Pharmaceuticals, Inc. (REGN) pays a dividend with a current yield of approximately 45.00%. The annualized dividend rate is $3.64 per share. The payout ratio is 9.0%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-08-18T00:00:00.000Z.
Key risks for Regeneron Pharmaceuticals, Inc. (REGN) investors include: 1. Moderate volatility (25.3% annualized)—price swings are notable. 2. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 3. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Regeneron Pharmaceuticals, Inc.'s (REGN) current debt and financial health profile: Total debt stands at $2.71B. The debt-to-equity ratio is 8.54, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 3.33, indicating strong short-term liquidity. The quick ratio is 2.63. The company holds $7.99B in cash and equivalents. Free cash flow is positive at $3.07B, providing a cushion for debt servicing and shareholder returns.